Date: 2017-03-27
Type of information: Capital increase
Company: Adaptimmune (UK)
Investors:
Amount: $61.8 million
Funding type: IPO
Planned used: Net proceeds will be be used to advance Adaptimmune’s wholly-owned pipeline of SPEAR® T-cell candidates through clinical trials as well as for other general corporate purposes. The company has four open INDs, including three for our wholly-owned SPEAR T-cells (AFP, MAGE-A4), for studies in 11 indications, 10 of which are solid tumors. In 2016, Adaptimmune has also formed a strategic alliance with MD Anderson Cancer Center to develop SPEAR T-cell therapies, including clinical studies of MAGE-A10 and MAGE-A4 SPEAR T-cell therapies. The company has entered strategic collaboration with Merck&Co to evaluate Keytruda® (pembrolizumab) in combination study with NY-ESO SPEAR T-cell therapy in multiple myeloma, with first site initiation anticipated in the first half of 2017.
A strategic collaboration has been initiated to evaluate Bellicum’s GoTCR technology (inducible MyD88/CD40 co-stimulation) with Adaptimmune’s affinity-optimized SPEAR T-cells. Adaptimmune has also expanded its strategic immunotherapy collaboration with GSK and announced GSK’s nomination of a second target, PRAME.
Others:
- • On March 27, 2017, Adaptimmune Therapeutics , a leader in T-cell therapy to treat cancer, announced the closing of its previously announced underwritten public offering of its American Depositary Shares. Adaptimmune sold 15,700,223 ADSs at a price to the public of $4.20 per ADS, which included 1,400,223 ADSs sold pursuant to the exercise of the underwriters’ option to purchase up to 2,145,000 additional ADSs. The net proceeds to Adaptimmune from the offering are approximately $61.8 million, after deducting the underwriting discount and other offering expenses payable by the company.
- • On March 22, 2017, Adaptimmune Therapeutics announced the pricing of an underwritten public offering of 14,300,000 of its American Depositary Shares at a price to the public of $4.20 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 2,145,000 ADSs at the public offering price. The gross offering size for this offering is expected to be approximately $ 60.1 million, excluding any exercise of the underwriters' option to purchase additional ADSs. This offering is expected to close on or about March 27, 2017, subject to customary closing conditions.
- • On March 21, 2017, Adaptimmune Therapeutics announced that it intends to offer and sell American Depositary Shares in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Citigroup, Cowen and Company and Leerink Partners are acting as joint book-running managers for the offering.
Therapeutic area: Cancer - Oncology
Is general: Yes
